PFAS forever chemicals could be a risk factor in thyroid cancer, Mount Sinai researchers find

FDA grants accelerated approval to selpercatinib for pediatric RET-altered metastatic thyroid cancer or solid tumors

FDA granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for pediatric patients two years of age and older

May 31, 2024

Vol.50 No.22

In Brief

Miriam Merad named dean for Translational Research and Therapeutic Innovation at Mt. Sinai

Miriam Merad was named dean for Translational Research and Therapeutic Innovation of the Icahn School of Medicine at Mount Sinai.

May 03, 2024

Vol.50 No.18

In Brief

Icahn School of Medicine at Mount Sinai receives $5M NCI grant for NIH Cancer Target Discovery and Development Center

The Department of Immunology and Immunotherapy and the Icahn Genomics Institute at the Icahn School of Medicine at Mount Sinai has received a $5 million grant from NCI to establish a center dedicated to the discovery and development of cutting-edge targets for cancer therapy.

November 17, 2023

Vol.49 No.43

Clinical Roundup

Mount Sinai researchers find more than 4,700 gene clusters crucial for prognosis in 32 cancer types

Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed “prognostic modules,” that significantly influence the progression of 32 different types of cancer.

November 17, 2023

Vol.49 No.43

In Brief

Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home

Krystal P. Cascetta, a 40-year-old New York City oncologist, and her 4-month-old infant daughter were found dead at a home in Somers, NY, Aug. 5 in what police describe as a possible murder-suicide.

August 11, 2023

Vol.49 No.32

Clinical Roundup

Researchers identify biological signature that may identify refractory ovarian cancer patients

Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Center, and University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy.

August 11, 2023

Vol.49 No.32

PFAS forever chemicals could be a risk factor in thyroid cancer, Mount Sinai researchers find

YOU MAY BE INTERESTED IN

FDA grants accelerated approval to selpercatinib for pediatric RET-altered metastatic thyroid cancer or solid tumors

Miriam Merad named dean for Translational Research and Therapeutic Innovation at Mt. Sinai

Icahn School of Medicine at Mount Sinai receives $5M NCI grant for NIH Cancer Target Discovery and Development Center

Mount Sinai researchers find more than 4,700 gene clusters crucial for prognosis in 32 cancer types

Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home

Researchers identify biological signature that may identify refractory ovarian cancer patients

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login